Inflammatory markers have a wide range of predictive values in the prognosis of non-small
lung cancer (NSCLC). Poor nutritional status usually means a poor prognosis in patients …

Peripheral blood inflammatory indices, like the neutrophil-to-lymphocyte ratio (NLR), may
reflect the host's pro-inflammatory status and systemic immune response to cancer-related …

To parallelly compare the efficacy of neoadjuvant immunotherapy (tislelizumab),
neoadjuvant chemotherapy (gemcitabine and cisplatin), and neoadjuvant combination …

Immunotherapies have recently gained traction as highly effective therapies in a subset of
late-stage cancers. Unfortunately, only a minority of patients experience the remarkable …

Introduction Pembrolizumab is an established first-line option for patients with advanced non-
small-cell lung cancer (NSCLC) expressing programmed death-ligand 1≥ 50%. Durable …

Background Efficacy outcomes and prognostic factors of real-world patients with advanced
non-small cell lung cancer (aNSCLC) treated with first-line chemoimmunotherapy are still …

Purpose of review To describe the biological rationale of peripheral blood cells (PBC)–
derived inflammatory indexes and assess the related prognostic scores for patients with …

Introduction PD-(L) 1 inhibitors (IO) have improved the prognosis of non-small-cell lung
cancer (NSCLC), but more reliable predictors of efficacy and immune-related adverse …

The emergence of immune checkpoint inhibitors (ICIs) has provided a new treatment option
for patients with hepatocellular carcinoma (HCC). However, further evaluation is needed for …

Methods: A literature search for randomized phase 2/3 trials on the treatment of early-stage
NSCLC was performed based on PubMed and the content on major oncology congresses …